Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

21. Systematic review and meta-analysis of the immunogenicity and reactogenicity of MF59-adjuvanted inactivated influenza vaccine among children aged <8 years

Systematic review and meta-analysis of the immunogenicity and reactogenicity of MF59-adjuvanted inactivated influenza vaccine among children aged <8 years Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

22. Reasons for low influenza vaccine uptake in pregnant women: providers and pregnant women perspectives

Reasons for low influenza vaccine uptake in pregnant women: providers and pregnant women perspectives Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

23. Influenza vaccination in older people: an umbrella review of systematic reviews with meta-analyses

Influenza vaccination in older people: an umbrella review of systematic reviews with meta-analyses Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

24. Individual patient data meta-analysis of intraseason waning of immunogenicity of seasonal influenza vaccine

Individual patient data meta-analysis of intraseason waning of immunogenicity of seasonal influenza vaccine Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

25. Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: a systematic review and meta-analysis

Effectiveness and safety of pneumococcal vaccines used alone or combined with influenza vaccination in dialysis patients: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

26. Influenza-associated disease burden in mainland China

Influenza-associated disease burden in mainland China Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

27. The effectiveness and efficacy of influenza vaccines among children: a systematic review of RCTs

The effectiveness and efficacy of influenza vaccines among children: a systematic review of RCTs Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

28. Effectiveness, Immunogenicity and Safety of Influenza Vaccines with MF59 Adjuvant in Healthy People in different Age: a Systematic Review and Meta-Analysis of Randomized Controlled Trials

Effectiveness, Immunogenicity and Safety of Influenza Vaccines with MF59 Adjuvant in Healthy People in different Age: a Systematic Review and Meta-Analysis of Randomized Controlled Trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility

2019 PROSPERO

29. Alternative dose versus standard dose of trivalent influenza vaccine for immunocompromised patients: a meta-analysis of randomized control trials

Alternative dose versus standard dose of trivalent influenza vaccine for immunocompromised patients: a meta-analysis of randomized control trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

30. Influenza and vaccination: efficacy and safety in diabetes

Influenza and vaccination: efficacy and safety in diabetes Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr

2019 PROSPERO

31. Effectiveness of seasonal influenza vaccination in preventing severe influenza in children: a systematic review

Effectiveness of seasonal influenza vaccination in preventing severe influenza in children: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

32. Health outcomes in offspring following exposure to maternal influenza infection in-utero: a systematic review

Health outcomes in offspring following exposure to maternal influenza infection in-utero: a systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

33. A systematic review of tools for predicting risk of complications of influenza-like illness

A systematic review of tools for predicting risk of complications of influenza-like illness Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external

2019 PROSPERO

34. Flucelvax Tetra - influenza vaccine

Flucelvax Tetra - influenza vaccine 30 Churchill Place ? Canary Wharf ? London E14 5EU ? United Kingdom An agency of the European Union Telephone +44 (0)20 3660 6000 Facsimile +44 (0)20 3660 5555 Send a question via our website www.ema.europa.eu/contact © European Medicines Agency, 2018. Reproduction is authorised provided the source is acknowledged. EMA/753449/2018 EMEA/H/C/004814 Flucelvax Tetra (influenza vaccine [surface antigen inactivated prepared in cell cultures]) An overview (...) of Flucelvax Tetra and why it is authorised in the EU What is Flucelvax Tetra and what is it used for? Flucelvax Tetra is a vaccine used to protect adults and children from 9 years of age against influenza (flu). Influenza is mainly caused by two kinds of influenza virus, known as influenza A and B. Each of these circulate as different strains and subtypes, which change over time. Flucelvax Tetra contains proteins from four different inactivated influenza A and B virus strains (type A-H1N1, type A-H3N2

2019 European Medicines Agency - EPARs

35. Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours

Baloxavir marboxil (Xofluza) - For the treatment of acute uncomplicated influenza in patients who have been symptomatic for no more than 48 hours Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Xofluza Film-Coated Tablets (Baloxavir marboxil) Company: Shionogi, Inc. Application Number: 210854 Approval Date: 10/24/2018 Persons with disabilities having problems accessing the PDF

2018 FDA - Drug Approval Package

36. Update: Can Newer Rapid Influenza Tests Rule Out Disease?

Update: Can Newer Rapid Influenza Tests Rule Out Disease? TAKE-HOME MESSAGE Although newer rapid in?uenza tests have improved our ability to rule out disease, they are still better at ruling in in?uenza. Change in management should be considered before testing. Update: Can Newer Rapid In?uenza Tests Rule Out Disease? EBEM Commentators Katie Pettit, MD Julie L. Welch, MD Department of Emergency Medicine Indiana University School of Medicine Indianapolis, IN Results Pooled diagnostic accuracy

2018 Annals of Emergency Medicine Systematic Review Snapshots

37. VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza

VAXIGRIPTETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments VAXIGRIPTETRA, vaccin quadrivalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à virion

2018 Haute Autorite de sante

38. INFLUVAC TETRA, tetravalent vaccine against seasonal influenza

INFLUVAC TETRA, tetravalent vaccine against seasonal influenza Haute Autorité de Santé - INFLUVAC TETRA, vaccin tétravalent contre la grippe saisonnière Développer la qualité dans le champ sanitaire, social et médico-social Recherche Évaluation & Recommandation La HAS Accréditation & Certification Outils, Guides & Méthodes Agenda Avis sur les Médicaments INFLUVAC TETRA, vaccin tétravalent contre la grippe saisonnière Substance active (DCI) vaccin grippal quadrivalent, inactivé, à antigènes de

2018 Haute Autorite de sante

39. The use of antiviral drugs for influenza: Guidance for practitioners

The use of antiviral drugs for influenza: Guidance for practitioners This practice point summarizes the use of antiviral drugs to manage influenza illness in children and youth. Recommendations are based on previously published Canadian recommendations for clinicians on the use of antiviral drugs to prevent and treat influenza. Detailed information on the selective use of chemoprophylaxis can be found in the original document, which also highlights the importance of secondary bacterial (...) infections (i.e., Streptococcus pneumoniae , methicillin-sensitive  Staphylococcus aureus and methicillin-resistant  S. aureus ) in cases of severe influenza illness. This document serves as a reference for all clinicians while providing general principles and a user-friendly flow diagram to assist decision-making. Keywords : Antiviral therapy; Children; Influenza; Neuraminidase inhibitors

2018 Canadian Paediatric Society

40. Vaccine recommendations for children and youth for the 2018/2019 influenza season

Vaccine recommendations for children and youth for the 2018/2019 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2018/2019 influenza season are not substantially changed from those of last season. Quadrivalent vaccine, if available, is recommended for children 6 months to 17 years of age. Either inactivated (...) influenza vaccine or live attenuated influenza vaccine may be used for children and youth 2 to 17 years of age who are not immunocompromised. Keywords:   Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

2018 Canadian Paediatric Society